BNP Paribas Asset Management
AMLX icon

BNP Paribas Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

BNP Paribas Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3K Sell
1,351
-67
-5% -$1.04K ﹤0.01% 1997
2026
Q1 		$19.7K Buy
1,418
+103
+8% +$1.45K ﹤0.01% 2038
2025
Q4 		$16K Buy
+1,315
New +$17.9K ﹤0.01% 2008

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BNP Paribas Asset Management's AMLX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 4.7% in Q2 2026, selling an estimated $1.04K and leaving 1,351 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

BNP Paribas Asset Management first reported a position in AMLX in Q4 2025 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • BNP Paribas Asset Management held 1,351 shares of Amylyx Pharmaceuticals worth $24.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 67 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.04K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1997 holding.
  • BNP Paribas Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.